The Wall Street Transcript
The Wall Street Transcript - In-Depth Interviews for Investors
Healthcare >> CEO Interviews >> April 29, 2025

Interview with the CEO: Abivax SA (NASDAQ:ABVX)

de Garidel, Marc
Marc de Garidel is the CEO of Abivax. Mr. de Garidel joined Abivax in May 2023. Prior to that, he led the successful sale of CinCor Pharma for up to US$1.8B, subject to the achievement of certain milestones, to AstraZeneca in February 2023, after joining the firm in July 2021. Mr. de Garidel also led the sale of Corvidia Therapeutics in August 2020 to Novo Nordisk for US$2.1B in total consideration after having joined the company as CEO in April 2018. He was the CEO of Ipsen from November 2010 to July 2016, overseeing the development of its U.S. presence. Prior to that, Mr. de Garidel worked for Amgen and Eli Lilly in jobs of increasing responsibilities in various international markets. He has served as Chairman of the Board of Ipsen since 2016 and has been a member of the board of directors of Claris Bio since 2020. Mr. de Garidel has a degree in civil engineering from the Ecole des Travaux Publics in Paris, a master’s degree in international management (MIM) from Thunderbird School of Global Management, and an executive MBA from Harvard Business School. Profile
Word count: 2,682

TWST: We’ve spoken before, but as a refresher for our readers, can you talk a little bit about the company, including some major milestones?

Mr. de

Top Company Interviews

Microsoft Corporation
Intel Corporation
Pfizer, Inc.
GE Aerospace (General Electric Company)
Walmart Inc.
International Business Machines Corporation
Citigroup Inc.
Exxon Mobil Corporation
Bank of America Corporation
Dell Inc.
Verizon Communications Inc.
Alphabet Inc
CEO INTERVIEWS
Interview with the Chairman, President and CEO: Puma Biotechnology, Inc. (NASDAQ:PBYI)
Interview with the President and CEO: NeurAxis, Inc. (NYSEAMERICAN:NRXS)
Interview with the Chairman and CEO: Mira Pharmaceuticals, Inc. (NASDAQ:MIRA) and Telomir Pharmaceuticals, Inc. (NASDAQ:TELO)
SECTOR ROUNDTABLES
Natural Gas Weighs Heavy On E&P Near-Term Prospects
Roundtable Forum:optimism Despite Uncertainty In For-profit Education
Roundtable Forum:a Shift In Focus To Natural Gas From Oil
MONEY MANAGER INTERVIEWS
Asymmetric Risk/Reward at Core of Multi-Asset Strategy
Dividend Growth Strategy Favors High-Quality Financials
Screening for 10% Dividend Growth Over 10 Years
ANALYST INTERVIEWS
Small Cap Med-Tech Names Are More Insulated from Tariff Fallout
Penumbra and AngioDynamics Among Top Med-Tech Sector Picks
Onshoring Drug Manufacturing Is Critical, But Not Easy
Since 1963
© The Wall Street Transcript 2016, 2025
Terms and Conditions
Privacy Policy